Literature DB >> 32665401

Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.

Catherine H Le1, Lindsay G Benage2, Kalyn S Specht3, Lance C Li Puma3, Christopher M Mulligan4, Adam L Heuberger5, Jessica E Prenni5, Steven M Claypool6, Kathryn C Chatfield7, Genevieve C Sparagna8, Adam J Chicco9,3,4.   

Abstract

Barth syndrome is a mitochondrial myopathy resulting from mutations in the tafazzin (TAZ) gene encoding a phospholipid transacylase required for cardiolipin remodeling. Cardiolipin is a phospholipid of the inner mitochondrial membrane essential for the function of numerous mitochondrial proteins and processes. However, it is unclear how tafazzin deficiency impacts cardiac mitochondrial metabolism. To address this question while avoiding confounding effects of cardiomyopathy on mitochondrial phenotype, we utilized Taz-shRNA knockdown (TazKD ) mice, which exhibit defective cardiolipin remodeling and respiratory supercomplex instability characteristic of human Barth syndrome but normal cardiac function into adulthood. Consistent with previous reports from other models, mitochondrial H2O2 emission and oxidative damage were greater in TazKD than in wild-type (WT) hearts, but there were no differences in oxidative phosphorylation coupling efficiency or membrane potential. Fatty acid and pyruvate oxidation capacities were 40-60% lower in TazKD mitochondria, but an up-regulation of glutamate oxidation supported respiration rates approximating those with pyruvate and palmitoylcarnitine in WT. Deficiencies in mitochondrial CoA and shifts in the cardiac acyl-CoA profile paralleled changes in fatty acid oxidation enzymes and acyl-CoA thioesterases, suggesting limitations of CoA availability or "trapping" in TazKD mitochondrial metabolism. Incubation of TazKD mitochondria with exogenous CoA partially rescued pyruvate and palmitoylcarnitine oxidation capacities, implicating dysregulation of CoA-dependent intermediary metabolism rather than respiratory chain defects in the bioenergetic impacts of tafazzin deficiency. These findings support links among cardiolipin abnormalities, respiratory supercomplex instability, and mitochondrial oxidant production and shed new light on the distinct metabolic consequences of tafazzin deficiency in the mammalian heart.
© 2020 Le et al.

Entities:  

Keywords:  Barth syndrome (BTHS); X-linked mitochondrial disorder; bioenergetics; cardiac metabolism; cardiolipin; cardioskeletal myopathy; lipid metabolism; mitochondrial disease; mitochondrial metabolism; phospholipid transacylase; tafazzin (TAZ)

Mesh:

Substances:

Year:  2020        PMID: 32665401      PMCID: PMC7458807          DOI: 10.1074/jbc.RA119.011229

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Long-term treatment of Barth syndrome with pantothenic acid: a retrospective study.

Authors:  Simone Rugolotto; Maria D Prioli; Daniela Toniolo; PierAntonio Pellegrino; Susanna Catuogno; Alberto B Burlina
Journal:  Mol Genet Metab       Date:  2003-12       Impact factor: 4.797

2.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification.

Authors:  Colin A Smith; Elizabeth J Want; Grace O'Maille; Ruben Abagyan; Gary Siuzdak
Journal:  Anal Chem       Date:  2006-02-01       Impact factor: 6.986

Review 3.  Cardiolipins and biomembrane function.

Authors:  F L Hoch
Journal:  Biochim Biophys Acta       Date:  1992-03-26

4.  Adaptive remodeling of skeletal muscle energy metabolism in high-altitude hypoxia: Lessons from AltitudeOmics.

Authors:  Adam J Chicco; Catherine H Le; Erich Gnaiger; Hans C Dreyer; Jonathan B Muyskens; Angelo D'Alessandro; Travis Nemkov; Austin D Hocker; Jessica E Prenni; Lisa M Wolfe; Nathan M Sindt; Andrew T Lovering; Andrew W Subudhi; Robert C Roach
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

5.  Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and interactions with aspartate aminotransferase and malate/aspartate shuttle.

Authors:  M Yudkoff; D Nelson; Y Daikhin; M Erecińska
Journal:  J Biol Chem       Date:  1994-11-04       Impact factor: 5.157

6.  Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.

Authors:  François Gonzalvez; Marilena D'Aurelio; Marie Boutant; Aoula Moustapha; Jean-Philippe Puech; Thomas Landes; Laeticia Arnauné-Pelloquin; Guillaume Vial; Nellie Taleux; Christian Slomianny; Ronald J Wanders; Riekelt H Houtkooper; Pascale Bellenguer; Ian Max Møller; Eyal Gottlieb; Frederic M Vaz; Giovanni Manfredi; Patrice X Petit
Journal:  Biochim Biophys Acta       Date:  2013-03-20

7.  Bicarbonate and the pathway of glutamate oxidation in isolated rat-liver mitochondria.

Authors:  R J Wanders; A J Meijer; A K Groen; J M Tager
Journal:  Eur J Biochem       Date:  1983-06-01

Review 8.  Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology.

Authors:  Erich Gnaiger
Journal:  Int J Biochem Cell Biol       Date:  2009-04-02       Impact factor: 5.085

9.  X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory-chain abnormalities in cultured fibroblasts.

Authors:  P G Barth; C Van den Bogert; P A Bolhuis; H R Scholte; A H van Gennip; R B Schutgens; A G Ketel
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

10.  Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome.

Authors:  Jan Dudek; I-Fen Cheng; Arpita Chowdhury; Katharina Wozny; Martina Balleininger; Robert Reinhold; Silke Grunau; Sylvie Callegari; Karl Toischer; Ronald Ja Wanders; Gerd Hasenfuß; Britta Brügger; Kaomei Guan; Peter Rehling
Journal:  EMBO Mol Med       Date:  2016-02-01       Impact factor: 12.137

View more
  8 in total

Review 1.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

Review 2.  Barth Syndrome Cardiomyopathy: An Update.

Authors:  Jing Pang; Yutong Bao; Kalia Mitchell-Silbaugh; Jennifer Veevers; Xi Fang
Journal:  Genes (Basel)       Date:  2022-04-08       Impact factor: 4.141

Review 3.  Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism.

Authors:  Volker Schirrmacher
Journal:  Biomedicines       Date:  2020-11-22

Review 4.  Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies.

Authors:  Christina Wasmus; Jan Dudek
Journal:  Life (Basel)       Date:  2020-11-11

5.  Chronic Lactate Exposure Decreases Mitochondrial Function by Inhibition of Fatty Acid Uptake and Cardiolipin Alterations in Neonatal Rat Cardiomyocytes.

Authors:  Iñigo San-Millan; Genevieve C Sparagna; Hailey L Chapman; Valerie L Warkins; Kathryn C Chatfield; Sydney R Shuff; Janel L Martinez; George A Brooks
Journal:  Front Nutr       Date:  2022-03-04

Review 6.  Myocardial disturbances of intermediary metabolism in Barth syndrome.

Authors:  Amanda A Greenwell; Seyed Amirhossein Tabatabaei Dakhili; John R Ussher
Journal:  Front Cardiovasc Med       Date:  2022-08-10

7.  Stimulating myocardial pyruvate dehydrogenase activity fails to alleviate cardiac abnormalities in a mouse model of human Barth syndrome.

Authors:  Amanda A Greenwell; Seyed Amirhossein Tabatabaei Dakhili; Keshav Gopal; Christina T Saed; Jordan S F Chan; Nick Kazungu Mugabo; Pavel Zhabyeyev; Farah Eaton; Jennifer Kruger; Gavin Y Oudit; John R Ussher
Journal:  Front Cardiovasc Med       Date:  2022-09-23

8.  Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.

Authors:  Patrice X Petit; Hector Ardilla-Osorio; Lucile Penalvia; Nathan E Rainey
Journal:  Cells       Date:  2020-10-21       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.